RO7234292 (RG6042)

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Huntington Disease

Conditions

Huntington Disease

Trial Timeline

Apr 23, 2019 → Mar 30, 2022

NCT ID

NCT03842969

About RO7234292 (RG6042)

RO7234292 (RG6042) is a phase 3 stage product being developed by Roche for Huntington Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03842969. Target conditions include Huntington Disease.

What happened to similar drugs?

1 of 10 similar drugs in Huntington Disease were approved

Approved (1) Terminated (2) Active (7)

✅TetrabenazineLundbeckApproved

🔄Votoplam (blinded) + PlaceboNovartisPhase 3

🔄RO7234292 + PlaceboRochePhase 3

🔄DimebonPfizerPhase 3

❌Dimebon (latrepirdine)PfizerPhase 3

🔄RiluzoleSanofiPhase 3

🔄ValbenazineNeurocrine BiosciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04000594	Phase 1	Completed	Sep 2, 2019	Jan 18, 2022	Huntingtons Disease
NCT03842969	Phase 3	Completed	Apr 23, 2019	Mar 30, 2022	Huntington Disease
NCT03342053	Phase 2	Completed	Jan 2, 2018	Oct 8, 2019	Huntington's Disease

Competing Products

20 competing products in Huntington Disease

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + Matching Placebo	Eli Lilly	Phase 2	35
Votoplam (blinded) + Placebo	Novartis	Phase 3	47
Votoplam	Novartis	Phase 2	39
Branaplam + Placebo	Novartis	Phase 2	27
AFQ056 + Placebo	Novartis	Phase 2	27
RO7234292 (RG6042)	Roche	Phase 1	29
Tominersen + Placebo	Roche	Phase 2	39
RO7234292 (RG6042)	Roche	Phase 2	35
RG6496 + Placebo	Roche	Phase 1	36
RO7234292 + Placebo	Roche	Phase 3	40
PF-02545920 + PF-02545920	Pfizer	Phase 2	35
Dextromethorphan + Dimebon + Dextromethorphan	Pfizer	Phase 1	29
Dimebon	Pfizer	Phase 3	40
Dimebon (latrepirdine)	Pfizer	Phase 3	32
20 mg BID of PF-02545920	Pfizer	Phase 2	27
PF-02545920 + Placebo + PF-02545920 + Placebo	Pfizer	Phase 2	35
Riluzole	Sanofi	Phase 3	40
ALN-HTT02 + Placebo	Alnylam Pharmaceuticals	Phase 1	33
Tetrabenazine	Lundbeck	Approved	36
Valbenazine	Neurocrine Biosciences	Phase 3	41